Business
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants
Strengthening balance sheet and capitalization is a key Jaguar priorityCompany continues its sharp, strategic focus on global development program for
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Strengthening balance sheet and capitalization is a key Jaguar priorityCompany continues its sharp, strategic focus on global development program for crofelemer for rare-disease intestinal failure indications SAN FRANCISCO, CA / ACCESS Newswire / March 9, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or \"the Company\") today announced that the Company has strengthened its balance sheet by restructuring and reducing its royalty obligations and debt held by affiliates of Chicago Venture Partners L.P., including the extinguishment of 48,212 warrants. The restructuring consisted of an initial reduction of approximately 10% (amounting to a reduction of approximately $3 million) of royalty obligations and debt; extending the maturity date by three years for a secured revolving line of credit for approximately $7 million put in place in November 2025; and ensuring that there are no maturity dates before July 2026 for any debt held by affiliates of Chicago Venture Partners L.P.\"We are very pleased to have completed this debt restructuring, and we plan to pursue additional potential opportunities to further restructure and reduce debt over the coming months in agreement with the debt holder,\" said Lisa Conte, Jaguar's founder, president, and CEO. \"Strengthening Jaguar's balance sheet and capitalization is a key priority. Operationally, we continue to sharply focus on our ongoing global development program for our crofelemer powder-for-oral-solution formulation for rare-disease intestinal failure indications. Our intestinal failure program is expected to continue to provide clinical proof-of-concept milestones and is the subject of business development discussions with the potential to bring in non-dilutive funds from potential licensee partners.\"About CrofelemerCrofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as \"dragon's blood,\" of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.About the Jaguar Health Family of CompaniesJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medic...